ProstaVysion examines three important genetic markers linked to prostate cancer, including DNA methylation of HOXD3, gene fusion/translocation analysis of ERG protein, and loss of the tumor suppressor gene PTEN.
Triple-positive results with these markers indicate a poor long-term prognosis, while triple-negative results indicate a favorable prognosis; this is important and actionable information for treatment choices.
Bostwick Laboratories chief medical officer David Bostwick said they believe that ProstaVysion successfully addresses the significant unmet need of defining how aggressive a specific prostate cancer is, empowering the patient and his physician to make the best possible treatment decision.
